Nifty
:
26046.95
Sensex
:
85267.66
148.40 (0.57%)
449.53 (0.53%)
Nifty
Sensex
:
:
26046.95
85267.66
148.40 (0.57%)
449.53 (0.53%)

Caplin Point Laboratories Ltd.

Pharmaceuticals & Drugs - Global

Rating :
65/99

BSE: 524742 | NSE: CAPLIPOINT

NSE BSE
1963.90
12-Dec-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1952
  •  1975.9
  •  1940
  •  1952.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  37297
  •  73152329.7
  •  2641
  •  1599

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 14,918.44
  • 25.34
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 14,271.84
  • 0.31%
  • 4.72

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 70.57%
  • 0.98%
  • 14.20%
  • FII
  • DII
  • Others
  • 6.48%
  • 2.05%
  • 5.72%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 23.29
  • 12.79
  • 9.72

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.99
  • 14.81
  • 7.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 27.90
  • 17.23
  • 12.54

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.06
  • 21.75
  • 25.21

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.30
  • 4.52
  • 4.81

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.54
  • 15.39
  • 17.15

Earnings Forecasts:

(Updated: 13-12-2025)
Description
2024
2025
2026
2027
Adj EPS
70.57
81.97
94.27
P/E Ratio
27.83
23.96
20.83
Revenue
1937.47
2194
2529.6
EBITDA
646.93
769.8
886.33
Net Income
536.31
620.75
781.05
ROA
18.16
22.45
23.43
P/B Ratio
5.38
4.41
3.95
ROE
21.38
19.51
19.16
FCFF
291.96
413.6
408.67
2918.72
FCFF Yield
2.11
2.98
2.95
21.04
Net Debt
-897.72
1385.2
1193.5
BVPS
365.2
445.39
496.84

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
534.04
483.10
10.54%
510.22
458.96
11.17%
502.45
453.22
10.86%
492.96
435.50
13.19%
Expenses
344.87
318.34
8.33%
332.46
307.15
8.24%
334.39
307.99
8.57%
330.67
293.22
12.77%
EBITDA
189.17
164.76
14.82%
177.76
151.81
17.09%
168.06
145.23
15.72%
162.29
142.28
14.06%
EBIDTM
35.42%
34.10%
34.84%
33.08%
33.45%
32.04%
32.92%
32.67%
Other Income
30.37
20.77
46.22%
23.14
18.56
24.68%
25.74
17.29
48.87%
31.36
17.18
82.54%
Interest
0.16
0.21
-23.81%
0.18
0.05
260.00%
0.17
0.15
13.33%
0.18
0.17
5.88%
Depreciation
18.40
16.76
9.79%
16.29
15.96
2.07%
17.04
16.40
3.90%
16.20
13.90
16.55%
PBT
200.98
168.56
19.23%
184.43
154.36
19.48%
176.59
145.97
20.98%
177.27
145.39
21.93%
Tax
40.77
37.65
8.29%
33.70
29.46
14.39%
31.39
24.80
26.57%
37.19
25.59
45.33%
PAT
160.21
130.91
22.38%
150.73
124.90
20.68%
145.20
121.17
19.83%
140.08
119.80
16.93%
PATM
30.00%
27.10%
29.54%
27.21%
28.90%
26.74%
28.42%
27.51%
EPS
20.32
17.21
18.07%
20.11
16.31
23.30%
18.76
16.01
17.18%
18.28
15.43
18.47%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
2,039.67
1,937.47
1,694.10
1,466.73
1,269.41
1,061.29
863.20
648.69
539.84
401.65
238.72
Net Sales Growth
11.41%
14.37%
15.50%
15.54%
19.61%
22.95%
33.07%
20.16%
34.41%
68.25%
 
Cost Of Goods Sold
802.09
770.84
724.18
663.21
557.51
471.74
413.16
288.78
238.18
184.93
121.16
Gross Profit
1,237.58
1,166.63
969.92
803.52
711.90
589.55
450.04
359.91
301.66
216.72
117.56
GP Margin
60.68%
60.21%
57.25%
54.78%
56.08%
55.55%
52.14%
55.48%
55.88%
53.96%
49.25%
Total Expenditure
1,342.39
1,290.54
1,142.66
1,026.21
874.88
737.04
603.13
416.84
344.52
276.84
174.51
Power & Fuel Cost
-
37.83
33.57
25.53
21.40
16.36
14.81
13.76
10.98
9.91
7.56
% Of Sales
-
1.95%
1.98%
1.74%
1.69%
1.54%
1.72%
2.12%
2.03%
2.47%
3.17%
Employee Cost
-
177.15
142.66
136.12
114.74
101.97
67.15
45.58
37.61
29.71
17.92
% Of Sales
-
9.14%
8.42%
9.28%
9.04%
9.61%
7.78%
7.03%
6.97%
7.40%
7.51%
Manufacturing Exp.
-
120.13
117.73
90.99
82.01
69.85
68.23
43.49
37.11
28.56
14.33
% Of Sales
-
6.20%
6.95%
6.20%
6.46%
6.58%
7.90%
6.70%
6.87%
7.11%
6.00%
General & Admin Exp.
-
112.05
92.97
85.38
66.68
38.53
25.50
20.82
12.27
13.78
8.15
% Of Sales
-
5.78%
5.49%
5.82%
5.25%
3.63%
2.95%
3.21%
2.27%
3.43%
3.41%
Selling & Distn. Exp.
-
62.25
24.88
18.78
27.52
18.03
9.95
2.08
5.92
9.41
2.29
% Of Sales
-
3.21%
1.47%
1.28%
2.17%
1.70%
1.15%
0.32%
1.10%
2.34%
0.96%
Miscellaneous Exp.
-
10.29
6.67
6.20
5.02
20.56
4.33
2.33
2.45
0.55
2.29
% Of Sales
-
0.53%
0.39%
0.42%
0.40%
1.94%
0.50%
0.36%
0.45%
0.14%
1.30%
EBITDA
697.28
646.93
551.44
440.52
394.53
324.25
260.07
231.85
195.32
124.81
64.21
EBITDA Margin
34.19%
33.39%
32.55%
30.03%
31.08%
30.55%
30.13%
35.74%
36.18%
31.07%
26.90%
Other Income
110.61
96.43
66.94
56.52
38.89
27.93
41.33
19.03
12.67
9.96
3.66
Interest
0.69
0.61
0.78
0.78
0.70
1.59
0.32
0.58
0.61
0.52
0.34
Depreciation
67.93
65.96
53.44
44.99
46.90
36.97
31.62
23.43
19.00
13.30
7.48
PBT
739.27
676.79
564.16
451.27
385.82
313.62
269.46
226.88
188.38
120.95
60.05
Tax
143.05
135.69
103.01
74.36
77.37
62.19
54.38
50.32
43.74
25.44
14.28
Tax Rate
19.35%
20.05%
18.26%
16.48%
20.05%
19.83%
20.18%
22.18%
23.22%
21.03%
23.78%
PAT
596.22
536.31
457.09
376.26
299.84
242.27
215.00
176.56
144.78
95.61
45.77
PAT before Minority Interest
588.66
541.09
461.42
376.99
308.45
251.43
215.08
176.56
144.63
95.50
45.77
Minority Interest
-7.56
-4.78
-4.33
-0.73
-8.61
-9.16
-0.08
0.00
0.15
0.11
0.00
PAT Margin
29.23%
27.68%
26.98%
25.65%
23.62%
22.83%
24.91%
27.22%
26.82%
23.80%
19.17%
PAT Growth
20.02%
17.33%
21.48%
25.49%
23.76%
12.68%
21.77%
21.95%
51.43%
108.89%
 
EPS
78.45
70.57
60.14
49.51
39.45
31.88
28.29
23.23
19.05
12.58
6.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
2,850.49
2,315.71
1,880.48
1,483.93
1,185.83
947.91
632.91
363.83
224.76
128.14
Share Capital
89.78
89.77
89.76
89.74
89.71
89.71
51.05
15.12
15.12
15.11
Total Reserves
2,741.06
2,211.72
1,775.35
1,378.74
1,081.33
848.76
575.01
345.42
209.56
111.40
Non-Current Liabilities
13.24
7.89
2.13
12.55
17.39
24.86
23.42
27.86
19.90
13.69
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.02
0.29
0.32
0.48
0.73
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
1.74
9.04
7.78
8.48
5.69
5.23
0.13
0.00
0.40
1.63
Current Liabilities
305.99
330.85
268.00
207.68
142.85
144.32
86.11
108.67
113.36
125.04
Trade Payables
217.58
229.62
152.56
155.94
88.50
64.14
60.47
94.23
78.60
55.71
Other Current Liabilities
64.28
90.29
99.94
48.68
51.87
79.28
24.20
13.86
33.09
60.39
Short Term Borrowings
0.55
0.28
3.41
0.50
0.00
0.00
0.00
0.00
0.00
0.00
Short Term Provisions
23.58
10.66
12.09
2.56
2.48
0.91
1.44
0.58
1.67
8.94
Total Liabilities
3,205.62
2,685.57
2,177.40
1,730.11
1,363.61
1,125.75
742.52
500.45
358.38
267.14
Net Block
545.78
452.66
279.81
286.57
305.34
272.50
226.84
169.48
151.83
144.23
Gross Block
859.52
702.31
480.32
445.74
422.58
354.79
271.51
231.79
195.15
180.76
Accumulated Depreciation
313.74
249.65
200.51
159.17
117.24
82.29
44.67
62.31
43.31
36.53
Non Current Assets
1,071.67
792.65
625.21
432.29
349.04
303.23
248.83
196.34
179.16
148.61
Capital Work in Progress
143.50
116.62
220.71
17.73
13.88
20.12
9.70
15.29
3.42
0.23
Non Current Investment
279.13
137.63
70.52
37.01
0.66
0.56
0.33
0.33
13.24
0.44
Long Term Loans & Adv.
88.61
78.31
51.51
89.90
7.92
10.05
11.95
11.23
10.67
3.71
Other Non Current Assets
14.65
7.43
2.66
1.08
21.24
0.00
0.00
0.00
0.00
0.00
Current Assets
2,133.95
1,892.92
1,552.19
1,297.82
1,014.57
822.53
493.69
304.11
179.22
118.53
Current Investments
311.33
237.98
210.18
51.97
10.54
60.23
69.62
46.34
4.20
0.00
Inventories
336.10
363.04
288.22
227.31
179.01
238.23
37.45
28.46
22.29
18.81
Sundry Debtors
632.49
542.72
394.06
317.05
279.36
228.96
159.81
125.88
33.02
7.95
Cash & Bank
591.41
552.74
493.48
462.99
438.33
223.43
152.99
79.28
93.07
68.10
Other Current Assets
262.62
50.43
22.82
13.61
107.33
71.68
73.83
24.16
26.63
23.67
Short Term Loans & Adv.
185.51
146.01
143.43
224.89
87.08
56.81
64.61
17.28
19.31
12.58
Net Current Assets
1,827.96
1,562.07
1,284.19
1,090.14
871.72
678.21
407.58
195.44
65.86
-6.51
Total Assets
3,205.62
2,685.57
2,177.40
1,730.11
1,363.61
1,125.76
742.52
500.45
358.38
267.14

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
432.37
318.39
271.37
336.73
268.61
44.68
83.42
66.49
67.61
42.40
PBT
676.78
564.43
451.35
385.82
313.62
269.46
226.88
188.38
120.95
60.05
Adjustment
5.51
2.40
11.77
30.44
23.09
7.09
19.12
14.84
8.61
3.87
Changes in Working Capital
-122.28
-139.44
-103.75
1.96
-1.96
-177.11
-120.06
-100.38
-38.39
-5.13
Cash after chg. in Working capital
560.01
427.39
359.37
418.22
334.75
99.44
125.94
102.84
91.16
58.78
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-127.64
-109.00
-88.00
-81.49
-66.14
-54.76
-42.51
-36.35
-23.55
-16.38
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-334.73
-320.04
-217.58
-376.77
-29.44
-54.50
-100.46
-69.02
-36.11
-5.72
Net Fixed Assets
-55.85
-18.39
-56.57
-3.66
-35.46
-43.65
58.45
-48.43
-19.56
-7.66
Net Investments
-218.29
-99.00
-220.45
-115.52
46.59
-27.53
-120.03
-29.43
-17.35
0.01
Others
-60.59
-202.65
59.44
-257.59
-40.57
16.68
-38.88
8.84
0.80
1.93
Cash from Financing Activity
-38.32
-38.07
-28.17
-40.68
-23.98
79.77
89.79
-11.60
-6.74
-13.95
Net Cash Inflow / Outflow
59.32
-39.72
25.62
-80.72
215.19
69.94
72.76
-14.13
24.76
22.73
Opening Cash & Equivalents
138.70
177.56
150.76
231.57
220.77
150.65
77.17
91.31
66.55
45.37
Closing Cash & Equivalent
193.74
134.20
170.92
150.76
435.72
220.77
150.65
77.17
91.31
68.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
362.67
293.21
235.91
183.89
144.94
114.21
78.03
47.69
29.73
16.25
ROA
18.37%
18.98%
19.30%
19.94%
20.20%
23.02%
28.41%
33.68%
30.54%
18.46%
ROE
21.72%
22.97%
23.68%
24.77%
25.65%
29.58%
37.14%
49.43%
54.97%
43.13%
ROCE
26.22%
26.92%
26.85%
28.77%
28.82%
33.35%
45.59%
64.08%
69.03%
55.41%
Fixed Asset Turnover
2.48
2.87
3.17
2.92
2.73
2.76
2.58
2.53
2.14
1.48
Receivable days
110.70
100.92
88.48
85.74
87.41
82.19
80.37
53.72
18.62
10.40
Inventory Days
65.86
70.16
64.15
58.42
71.75
58.28
18.54
17.16
18.68
24.83
Payable days
105.88
96.31
84.89
80.02
59.05
28.33
65.76
89.68
88.17
103.48
Cash Conversion Cycle
70.68
74.76
67.73
64.14
100.11
112.15
33.15
-18.80
-50.88
-68.24
Total Debt/Equity
0.00
0.00
0.00
0.00
0.01
0.04
0.00
0.00
0.00
0.02
Interest Cover
1110.48
724.63
579.65
552.17
198.25
843.86
391.22
309.72
235.08
179.35

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Caplin Point Laboratories’ arm gets USFDA’s nod for Linezolid Injection
    9th Dec 2025, 15:28 PM

    Linezolid Injection is an anti-bacterial primarily used to treat serious bacterial infections, including pneumonia and skin infections, particularly those resistant to other antibiotics

    Read More
  • Caplin Point Laboratories’ arm gets USFDA’s final approval for Acetaminophen Injection
    8th Dec 2025, 16:15 PM

    Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older

    Read More
  • Caplin Point Lab - Quarterly Results
    6th Nov 2025, 00:00 AM

    Read More
  • Caplin Point’s arm gets USFDA’s approval for Nicardipine Hydrochloride in Sodium Chloride Injection
    23rd Oct 2025, 16:42 PM

    Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.